Kilitch Drugs (India) (NSE:KILITCH) Moat Score: 0/10 (As of Jul. 09, 2026)


NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
85 GF Score
Price ₹184.24
GF Value ₹226.20
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Moat Score?

Kilitch Drugs (India) has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Kilitch Drugs (India) has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kilitch Drugs (India) might have No Moat - No discernible moat.

Kilitch Drugs (India)  (NSE:KILITCH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kilitch Drugs (India) Moat Score Related Terms

NSE:KILITCH
85GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹184.24 is trading 18.5% below its estimated GF Value™ of ₹226.20. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Moat Score: 0
  • GF Value™: ₹226.20 vs. price of ₹184.24 (18.5% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
85GF Score

Get the complete analysis for NSE:KILITCH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹184.24
Price
₹226.20
GF Value